ALX ONCOLOGY HOLDINGS INC — Form SCHEDULE 13D/A
Filed October 16, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
VenBio Global Strategic Fund L.P. and VenBio Global Strategic Fund II L.P. (and related entities) executed a joint filing agreement dated October 16, 2026, to file a Schedule 13D amendment jointly on behalf of all parties. This is a procedural document satisfying SEC Rule 13d-1(k)(1)(iii); no specific shareholding amounts, percentages, or transaction details are disclosed in this excerpt.
Why this rating
Joint filing agreement is standard procedural SEC compliance. No new holdings, transactions, or material changes disclosed. Routine 13D administrative filing.
See more from October 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.